GCG and Parkinson disease: However, the GLP-1 and GIP receptor agonists may differ in their neuroprotective effects in view of pharmacodynamic and pharmacokinetic differences, and it is not quite clear if they would act as adjuvants in the treatment of PD with other usual antiparkinsonian drugs, or if they really could alter the progression of the disease.